Anxiety and depression in bronchiectasis: Response to pulmonary rehabilitation and minimal clinically important difference of the Hospital Anxiety and Depression Scale
| Autor: | Suhani Patel, Ruth E Barker, Michael R. Loebinger, William D.-C. Man, Robert Wilson, Samantha S.C. Kon, Sarah Jones, Jessica A. Walsh, Stephanie C Wynne, Claire M. Nolan, Julius Cairn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male medicine.medical_specialty bronchiectasis medicine.medical_treatment Respiratory System Anxiety Hospital Anxiety and Depression Scale Severity of Illness Index 03 medical and health sciences Pulmonary Disease Chronic Obstructive 0302 clinical medicine Internal medicine Surveys and Questionnaires London Outcome Assessment Health Care Medicine Humans Pulmonary rehabilitation 030212 general & internal medicine 1102 Cardiorespiratory Medicine and Haematology Depression (differential diagnoses) Psychiatric Status Rating Scales COPD Original Paper Bronchiectasis business.industry Minimal clinically important difference minimal clinically important difference 1103 Clinical Sciences Middle Aged medicine.disease pulmonary rehabilitation Mood Treatment Outcome 030228 respiratory system depression Quality of Life Female medicine.symptom business |
| Zdroj: | Chronic Respiratory Disease |
| Popis: | The aims of the study were to evaluate the responsiveness of Hospital Anxiety and Depression Scale-Anxiety (HADS-A) subscale and HADS-Depression (HADS-D) subscale to pulmonary rehabilitation (PR) in patients with bronchiectasis compared to a matched group of patients with chronic obstructive pulmonary disease (COPD) and provide estimates of the minimal clinically important difference (MCID) of HADS-A and HADS-D in bronchiectasis. Patients with bronchiectasis and at least mild anxiety or depression (HADS-A ≥ 8 or/and HADS-D ≥ 8), as well as a propensity score-matched control group of patients with COPD, underwent an 8-week outpatient PR programme (two supervised sessions per week). Within- and between-group changes were calculated in response to PR. Anchor- and distribution-based methods were used to estimate the MCID. HADS-A and HADS-D improved in response to PR in both patients with bronchiectasis and those with COPD (median (25th, 75th centile)/mean (95% confidence interval) change: HADS-A change: bronchiectasis −2 (−5, 0), COPD −2 (−4, 0); p = 0.43 and HADS-D change: bronchiectasis −2 (−2 to −1), COPD −2 (−3 to −2); p = 0.16). Using 26 estimates, the MCID for HADS-A and HADS-D was −2 points. HADS-A and HADS-D are responsive to PR in patients with bronchiectasis and symptoms of mood disorder, with an MCID estimate of −2 points. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|